ReviewCritical care medicine2009
Diabetes, insulin, and development of acute lung injury.
Review in Critical care medicine, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed, 1 synthesis or guideline pooled it, 126 citations in OpenAlex.
- Pooled it
- Trial
- Impact of diabetes medications and HbA1c levels on abdominoplasty and panniculectomy outcomes.JPRAS open · 2025Article
- Elevated Hemoglobin A1c and the Risk of Developing ARDS in Two Cohort Studies.CHEST critical care · 2024Article
- Mitochondrial function in lungs of rats with different susceptibilities to hyperoxia-induced acute lung injury.Journal of applied physiology (Bethesda, Md. : 1985) · 2024Article
- Outpatient insulin use in type 2 diabetes mellitus and acute respiratory distress syndrome outcomes: A retrospective cohort study.World journal of clinical cases · 2024Article
- Secondary Analysis of Fluids and Catheters Treatment Trial (FACTT) data reveal poor clinical outcomes in acute respiratory distress syndrome patients with diabetes.Respiratory medicine · 2024Article
- Diabetes associates with mortality in critically ill patients with SARS-CoV-2 pneumonia: No diabetes paradox in COVID-19.Heliyon · 2023Article
- Type 1 diabetes and diet-induced obesity predispose C57BL/6J mice to PMParticle and fibre toxicology · 2023Article
- Article
- Analysis between ABO blood group and clinical outcomes in COVID-19 patients and the potential mediating role of ACE2.Frontiers in medicine · 2023Article
- New-onset diabetes in COVID-19: The molecular pathogenesis.BioMedicine · 2023Review
- In vivo molecular imaging stratifies rats with different susceptibilities to hyperoxic acute lung injury.American journal of physiology. Lung cellular and molecular physiology · 2022Article
- Relationship between hyperglycemia, waist circumference, and the course of COVID-19: Mortality risk assessment.Experimental biology and medicine (Maywood, N.J.) · 2022Observational
- A trauma-related survival predictive model of acute respiratory distress syndrome.Journal of clinical laboratory analysis · 2021Article
- Type 2 diabetes mellitus and sepsis: state of the art, certainties and missing evidence.Acta diabetologica · 2021Review
- Diabetic Pneumopathy-A New Diabetes-Associated Complication: Mechanisms, Consequences and Treatment Considerations.Frontiers in endocrinology · 2021Review
- Should ACE2 be given a chance in COVID-19 therapeutics: A semi-systematic review of strategies enhancing ACE2.European journal of pharmacology · 2020Review
- Article
- Management of diabetes in patients with COVID-19.The lancet. Diabetes & endocrinology · 2020Article
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
objectivesRecently, many studies have investigated the immunomodulatory effects of insulin and glucose control in critical illness. This review examines evidence regarding the relationship between diabetes and the development of acute lung injury/acute respiratory distress syndrome (ALI/ARDS), reviews studies of lung injury related to glycemic and nonglycemic metabolic features of diabetes, and examines the effect of diabetic therapies. DATA SOURCES AND STUDY SELECTION: A MEDLINE/PubMed search from inception to August 1, 2008, was conducted using the search terms acute lung injury, acute respiratory distress syndrome, hyperglycemia, diabetes mellitus, insulin, hydroxymethylglutaryl-CoA reductase inhibitors (statins), angiotensin-converting enzyme inhibitor, and peroxisome proliferator-activated receptors, including combinations of these terms. Bibliographies of retrieved articles were manually reviewed. DATA EXTRACTION AND SYNTHESIS: Available studies were critically reviewed, and data were extracted with special attention to the human and animal studies that explored a) diabetes and ALI; b) hyperglycemia and ALI; c) metabolic nonhyperglycemic features of diabetes and ALI; and d) diabetic therapies and ALI.
conclusionsClinical and experimental data indicate that diabetes is protective against the development of ALI/ARDS. The pathways involved are complex and likely include effects of hyperglycemia on the inflammatory response, metabolic abnormalities in diabetes, and the interactions of therapeutic agents given to diabetic patients. Multidisciplinary, multifaceted studies, involving both animal models and clinical and molecular epidemiology techniques, are essential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.